Navigation Links
PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
Date:5/6/2008

- Data Presented in Poster Session at American College of Obstetricians and

Gynecologists' 56th Annual Clinical Meeting -

PALO ALTO, Calif., May 6 /PRNewswire/ -- PEAK Surgical, Inc., a medical device company that is developing new tissue dissection systems based on a proprietary technology, released results from a preclinical study demonstrating that its PEAK PlasmaBlade(TM) cut freshly excised human abdominal tissue with little thermal tissue injury compared with traditional electrosurgery. The PEAK PlasmaBlade is a low-temperature tissue dissection tool that uses pulsed plasma energy to create surgical incisions and control bleeding.

The data also showed improved surgical incision wound healing in an in vivo porcine model compared to traditional electrosurgery. The results were presented in a poster session at the American College of Obstetricians and Gynecologists' (ACOG) 56th Annual Clinical Meeting in New Orleans by lead investigator Dr. Paul Blumenthal, M.P.H., professor in the Department of Obstetrics and Gynecology at Stanford University School of Medicine.

"The findings of this comparative preclinical study of tissue cutting and healing are encouraging because they demonstrated that cuts made with the PEAK PlasmaBlade produced minimal collateral damage compared with cuts made with currently available electrosurgical instruments," Dr. Blumenthal said. "This is important because collateral tissue damage may impede wound healing, obscure histological analysis, and lead to scarring and infection in surgical patients. New surgical cutting tools that use less heat but offer precise soft-tissue cutting and coagulation with minimal thermal injury could change the way we operate."

The PEAK Surgery System is not yet available in the United States. The company has filed a 510(k) pre-market notification with the U.S. Food and Drug Administration to market the system in the United States.

Study Design

In the
'/>"/>

SOURCE PEAK Surgical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
2. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
3. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
4. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
5. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
6. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
10. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
11. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...cal Incorporated (Nasdaq: VICL ) announced today...rom Merck & Co., Inc. based on Merck,s planned...stigational plasmid DNA (pDNA) cancer vaccine. The...livery technology and encodes human telomerase rev...f separate license agreement. , , "The brea...
(Date:11/28/2008)...- Eli Lilly and Company,(NYSE: LLY ) has withdr...rom,the U.S. Food and Drug Administration (FDA) f...t of chronic pain. Lilly plans to resubmit the app...rom a recently completed positive study,in chroni...cision does not affect duloxetine,s FDA-approved i...
(Date:11/26/2008)...KLIN, Mass., Nov. 26 PLC...d today that it has received full approval from th...U.S. pivotal trial to study the effectiveness of t... therapy in the prevention of Contrast-Induced Nep...LC,s request to expand their investigation from th...
(Date:11/25/2008)...re/ -- Proteolix, Inc., a,leader in the discovery...,protein degradation pathways in cancer and autoi...o ongoing Phase 2 clinical trials of carfilzomib i...ing 50th Annual Meeting of the,American Society o... new class,of specific proteasome inhibitors and ...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 1LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 2DFG continues to strengthen biodiversity research 5543 1DFG continues to strengthen biodiversity research 5543 2Innovative strategies for war wounded 5538 1Innovative strategies for war wounded 5538 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 1Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 3
...lso Support Drug,s Efficacy at Improving Glycemic ...ications, CHICAGO, Ill., June 23, 2007 /PRNewswire...mercialization partner S2 Therapeutics,Inc., repo...trial,supporting the overall and cardiovascular sa...of bromocriptine mesylate) in subjects,with type 2...
...R CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gi...that Study 103, a,Phase III clinical trial evaluat...R) (tenofovir disoproxil fumarate or tenofovir,DF)...itis B virus,(HBV) infection, met its primary effi...ferior to the company,s once-daily antiviral,drug ...
Other Medicine Technology:Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
(Date:12/1/2008)... Dec. 1 Actavis Group, the interna...unced that it has received approval from the U.S. ... Hydrochloride extended-release tablets (XL) 150mg... , Bupropion Hydrochloride extended-release ...h, are the generic equivalent of Wellbutrin XL(R) ...
(Date:12/1/2008)... , Ideas from U-M physician include economical... A bottle of cologne, a... and easy gifts to buy and wrap for the upcoming h...ng more healthy and beneficial to a loved one? Why...healthy around the holidays can be challenging, an...
(Date:12/1/2008)...PRNewswire/ -- Resurrection Health Care has been r...lthcare by Modern Healthcare,magazine. The nation...ing,homes, retirement communities, home health se...ices throughout the Chicago area. , Modern ...s health care,organizations nationwide that enabl...
(Date:12/1/2008)... 1 Prior generations often shared,...ents -- typically because,seniors didn,t live far...h,life expectancy having increased by an average ...mbered by health care concerns, which may make old...emselves. In the recently published,Evercare(R) S...
Breaking Medicine News(10 mins):Health News:Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S. 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:Resurrection Health Care Named One of Nation's 'Best Places to Work in Healthcare' 2Health News:Take Time to Care for the Caregiver 2
... the brain of youngsters, says a study, which stre... can do to them. // Thomas Heffernan, a psychologi...llege students for the research presented at the B...s annual conference in York, reported the online e...
...r still remains the best way to ensure patient s...ring the 85th General Session of the International...the University of California-Irvine presented two ...approaches to oral cancer detection, diagnostic sc...
...m Aberdeen University are on the brink of another ...s of lives,// by an early diagnosis of cancer, Alz...ther disorders. A prototype of an MRI scanner has...ferent images, compared to one image from current ...
...oon urged governments to join the anti-tuberculosi...n coming years as// the disease has become extreme...ng the importance of World TB Day on Saturday. The...tly reported about the rise in the extensively dru...
Other Medicine News:Health News:Novel Methods in Diagnosing Oral Cancer 2Health News:Breakthrough in MRI Scanning in the Near Future 2
15" overall length, 9" handle.
Gimmi Yasargil Aneurysm-Vessel-Clips
Yasargil Phynox Aneurysm Clips Standard
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in
Medicine Products: